本報告已在2011年07月19日停止出版。
蛋白質體學可以降低治療癌症及阿耳茲海默病的新藥 R＆D 的成本，帶來新的獲利機會。
專門從事各產業領域內成長市場的策略性調查的英國市調公司 Business Insight（總公司：倫敦），詳盡地調查與分析伴隨著蛋白質體學發展的個人醫療狀況，並有系統地出版綜合報告書 "The Future of Personalized Medicine: The impact of proteomics on drug discovery and clinical trial design" 。
此報告書使用包括 39 張圖表在內的 154 頁篇幅，分析蛋白質體學如何運用在藥物開發上，以及如何提高個人醫療開發市場的經濟效益。此報告書的概略架構如下所示。
摘要
1. 蛋白質體學的說明
- 摘要
- 說明
- 人體基因組與蛋白質體
- 蛋白質體與基因的關係
2. 蛋白質體學技術
- 摘要
- 實驗室所使用的蛋白質體學技術
- 自動化
- 生物資訊與資料庫
- 綜合結論
3. 蛋白質體學應用在藥物開發的使用
- 摘要
- 說明
- R＆D 過程的最優化
- 在新藥候補初期階段的選擇
- 在候補治療藥中發現新藥劑的效率提升
4. 臨床實驗設計與蛋白質體學應用在個人醫療的使用
- 摘要
- 新生物標識的研發
- 各治療領域內生物標識的使用
- 生物標識在新藥中的使用
- 結論
5. 醫療品企業與蛋白質體學企業的合作
Abstract
Personalized Medicine: The impact of proteomics on drug discovery and
clinical trial design is a management report that analyses how proteomics will
streamline drug development and lead to the more cost-effective development of
niche personalized products of the future.
Proteomics promises lower R&D costs and the opportunities of new revenue
streams through the identification of new drug targets in the treatment of
diseases such as cancer and Alzheimers. Use this report to identify the most
important technologies, their applications in drug discovery and clinical trial
design and the leading companies driving development of this exciting new area.
The pharmaceutical industry has so far been slow to take up proteomic
technology and strategic alliances and acquisitions will be central to the
pharmaceutical industrys uptake of proteomics. This report identifies the key
technologies that will enable pharmaceutical companies to develop new niche
products, improve drug attrition rates, increase the speed of clinical
development and target new drug markets.
Key findings of the report
Proteomics has the potential to reduce drug development time and drug
attrition rates. If total development time is reduced by three years and the
number of successful NDAs doubled, R&D costs could be cut by as much as 30%
per year. Companies investing in proteomics to target niche markets can reap
considerable financial rewards as exemplified by Gleevec (Novartis) and
Herceptin (Roche) which generated around $1bn in worldwide sales in 2003. There
is a high unmet clinical need for early disease detection, such as in cancer and
neurodegenerative diseases. The development of diagnostic tools using
"biomarkers" has the potential to result in better prognosis for
patients and to satisfy this unmet need. More that $700m has been invested in
proteomics companies by venture capitalists and through IPOs (Initial Public
Offerings) in the last four years. As the main bottleneck in proteomics is the
ability to analyze the colossal amount of data generated, it is essential for
companies to invest heavily in bioinformatics.
Table of Contents
CHAPTER 1: INTRODUCTION TO PROTEOMICS
- The human genome versus the proteome
- Identification of human genome
- Applications to proteomics
- The relationship between the proteome and the genome
- The genome
- Proteins
- From genes to proteins
- Proteomics
CHAPTER 2: PROTEOMIC TECHNOLOGIES
- Laboratory methods used in proteomics
- Separation techniques
- Identification techniques
- Interactions techniques
- Separation techniques
- Identification techniques
- Protein-protein interaction techniques
- Automation
- Pre-fractionation
- Separation
- Identification
- Complete proteomics solutions
- Bioinformatics and databases
- Data Analysis
- Databases
- Laboratory information management systems (LIMS)
CHAPTER 3: PROTEOMIC APPLICATIONS IN DRUG DISCOVERY
- Optimizing the R&D process
- Early selection of efficacious and non-toxic drug targets
- Toxicoproteomics
- Pharmacoproteomics
- Accelerating the discovery of new targets for therapeutic candidates
- Therapeutic proteins
- Protein targets
- Mining the proteome is an alternative approach for drug discovery
CHAPTER 4: PROTEOMIC APPLICATIONS IN CLINICAL TRIAL DESIGN AND
PERSONALIZED MEDICINE
- Development of new biomarkers
- Biomarkers as clinical endpoints
- Responders and non-responders
- Patients with adverse reactions
- Patients in different stages of a disease, or other subsets of patients
- Monitor clinical responses in new and comparator drugs - allowing
potential strategic alliances
- Patients with disease resistance
- Niche markets
- Application of biomarkers in different therapy areas
- Oncoproteomics
- Application in the diagnosis of: ovarian
- cancer, prostate cancer, breast cancer and
- esophageal cancer
- Neuroproteomics Application in the diagnosis of:
- Alzheimers diseases and amyotrophic lateral sclerosis (ALS)
- Cardioproteomics
- Cardiovascular markers
- Respiratory markers
- Application in organ transplantation
- Post-marketing applications of biomarkers
CHAPTER 5: PHARMACEUTICAL AND PROTEOMIC COMPANY ALLIANCES
- Recent collaborations and alliances of pharmaceutical and proteomic based
companies
